stoxline Quote Chart Rank Option Currency Glossary
  
Chinook Therapeutics, Inc. (KDNY)
40.39  0.09 (0.22%)    08-10 16:00
Open: 40.31
High: 40.51
Volume: 3,281,100
  
Pre. Close: 40.3
Low: 40.295
Market Cap: 2,708(M)
Technical analysis
2023-09-01 4:48:09 PM
Short term     
Mid term     
Targets 6-month :  47.31 1-year :  55.26
Resists First :  40.5 Second :  47.31
Pivot price 40.26
Supports First :  39.49 Second :  38.86
MAs MA(5) :  40.38 MA(20) :  39.96
MA(100) :  30.31 MA(250) :  25.67
MACD MACD :  0.7 Signal :  0.9
%K %D K(14,3) :  92.4 D(3) :  92.4
RSI RSI(14): 78.4
52-week High :  40.5 Low :  18.34
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ KDNY ] has closed below upper band by 39.2%. Bollinger Bands are 79.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 40.43 - 40.62 40.62 - 40.79
Low: 39.91 - 40.14 40.14 - 40.34
Close: 40.05 - 40.4 40.4 - 40.71
Company Description

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

Headline News

Wed, 29 May 2024
Chinook Therapeutics (KDNY) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Movies UK

Fri, 28 Jul 2023
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301 ... - GlobeNewswire

Fri, 07 Jul 2023
Meet The Company Novartis Is Spending $3.5 Billion To Acquire - Investor's Business Daily

Wed, 21 Jun 2023
Chinook: Acquisition By Novartis, Deal Should Go Through (NASDAQ:KDNY) - Seeking Alpha

Mon, 12 Jun 2023
Carson Block's Latest Short Bet Is Burned by Novartis M&A Deal - Bloomberg

Mon, 12 Jun 2023
Chinook Therapeutics Shares Soar on Novartis Purchase - Investopedia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 67 (M)
Held by Insiders 6.116e+007 (%)
Held by Institutions 2.1 (%)
Shares Short 3,130 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.2809e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 998.1 %
Return on Equity (ttm) -26.9 %
Qtrly Rev. Growth 5.85e+006 %
Gross Profit (p.s.) 210.59
Sales Per Share -84.86
EBITDA (p.s.) -2.01612e+008
Qtrly Earnings Growth -3.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -174 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -1.4
Price to Book value 0
Price to Sales -0.48
Price to Cash Flow 5.08
Stock Dividends
Dividend 0
Forward Dividend 2.88e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android